Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19330960 | 0.87 | CHRM2 (0.47) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL19331369 | 0.82 | LMNA (0.52) | MEN1KMT2AL3MBTL1ALDH1A1POLB | |
| SCHEMBL19330837 | 0.81 | OPRL1 (0.57) | MEN1KMT2AALDH1A1POLBCYP2D6 | |
| SCHEMBL29087415 | 0.79 | CCR3 (0.61) | KMT2APOLBCYP3A4 | |
| SCHEMBL19331018 | 0.77 | OPRL1 (0.47) | KMT2AALDH1A1MAPTPOLBLMNA | |
| SCHEMBL15033015 | 0.76 | MEN1 (0.58) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL6167989 | 0.76 | LMNA (0.63) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL23862832 | 0.75 | CRBN (0.44) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL2089472 | 0.75 | CYP2D6 (0.53) | MEN1KMT2AL3MBTL1ALDH1A1LMNA | |
| SCHEMBL21100967 | 0.75 | KDM1A (0.74) | KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3884939-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3884939-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3426243-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| WO-2017156165-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | MEN1 3285/4885KMT2A 2306/4885L3MBTL1 1216/4885 |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | MEN1 3285/4885KMT2A 2306/4885L3MBTL1 1216/4885 |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | MEN1 3285/4885KMT2A 2306/4885L3MBTL1 1216/4885 |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | MEN1 3285/4885KMT2A 2306/4885L3MBTL1 1216/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | MEN1 3285/4885KMT2A 2306/4885L3MBTL1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.